The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients With Type 2 Diabetes Mellitus
| Autor: | Qijuan He, Jinxing Quan, Weiya Shi, Jing Liu, Yonghong Li, Yaqiong Zhang, Yaya Lv, Juxiang Liu, Suhong Wei, Zubang Zhou |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine China medicine.medical_specialty Type 2 diabetes 030204 cardiovascular system & hematology Carotid Intima-Media Thickness Proinflammatory cytokine Pathogenesis 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Diabetes mellitus medicine Humans Endothelial dysfunction Subclinical infection business.industry Type 2 Diabetes Mellitus General Medicine Middle Aged Atherosclerosis medicine.disease Neoplasm Proteins 030104 developmental biology Endocrinology Diabetes Mellitus Type 2 Biomarker (medicine) Female Proteoglycans business Biomarkers Blood Chemical Analysis |
| Zdroj: | The American Journal of the Medical Sciences. 353:433-438 |
| ISSN: | 0002-9629 |
| DOI: | 10.1016/j.amjms.2017.02.004 |
| Popis: | Proinflammatory conditions induced by circulating factors in diabetes play a pivotal role in endothelial dysfunction and related vascular complications. Endothelial cell-specific molecule-1 or endocan is a dermatan sulfate proteoglycan secreted primarily by the vascular endothelium. Although endocan has been shown to be a potential biomarker in coronary heart disease, its role in the pathogenesis of atherosclerosis (AS) in diabetes remains unclear. In this study, we investigated the correlation between serum endocan levels and subclinical AS in patients with type 2 diabetes mellitus (T2DM).Patients (n = 69) with T2DM were included. All the patients were stratified based on the absence (n = 42) or presence (n = 27) of subclinical AS. Healthy subjects (n = 28) served as controls. Serum levels of endocan, fasting blood glucose, glycosylated hemoglobin A1, high-sensitivity C-reactive protein and carotid intima-media thickness (cIMT) were measured.Endocan levels were significantly elevated in both the T2DM (0.89 ± 0.28ng/mL) and T2DM with subclinical AS (1.20 ± 0.33ng/mL) groups relative to the control group (0.68 ± 0.24ng/mL) (P0.05 for all). Endocan levels were also positively correlated with glycosylated hemoglobin A1, fasting blood glucose and cIMT (r = 0.292, P = 0.004; r = 0.224, P = 0.027 and r = 0.496, P0.001, respectively). In addition, endocan levels were independently associated with cIMT (β = 0.220, t = 5.816, P = 0.000) and were a significant risk factor for T2DM with subclinical AS (odds ratio = 1.98, 95% CI: 1.43-2.73, P0.001).These findings suggest that serum endocan levels may be a useful biomarker for the early diagnosis of subclinical AS in patients with T2DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|